Women's Health: Just a lifestyle tool or a full-blown medical device?
Please confirm you are human to start the audio.
Authors
Women's health is one of the fastest-growing sub-markets in the healthcare sector. Digital services in particular are thriving, including menstrual cycle and fertility apps, linked sensors for measuring temperature, pelvic floor trainers linked to an app, digital tools to help with menopausal symptoms and breast self-examination apps. Manufacturers are regularly faced with the question of whether what they are offering is a lifestyle or consumer product that can be freely marketed or a medical device subject to the EU Medical Devices Regulation (MDR).
When is a women's health product classified as a medical device?
The MDR ties classification as a medical device primarily to the purpose intended by the manufacturer (Article 2 no. 1 and no. 12 MDR). The decisive factor is the intended purpose of the product as stated by the manufacturer – for example on the packaging and in the instructions for use but also in promotional materials, in the app store or on social media. A menstrual cycle app that is intended solely for general self-monitoring and wellbeing is outside the scope of the MDR for now. However, if the same app is marketed with the aim of preventing pregnancy or determining the fertile window for targeted family planning, its intended purpose changes – and with it potentially its regulatory classification.
Nevertheless, the manufacturer's subjective intended purpose is only relevant insofar as it is objectively scientifically sound and consistent with the product's actual functionality. Classifying a fertility app as just a wellness tool even though it provides specific contraceptive advice based on physiological measurements risks that classification being corrected by the authorities or the courts. What is crucial in each case is whether, based on its intended purpose, the product performs diagnostic or therapeutic functions related to a disease or physiological condition or whether it is limited to general wellbeing and lifestyle functions.
EU MDR: What requirements apply to women's health products?
When a women's health product falls within the scope of the MDR, the regulatory burden depends largely on the risk class. In many cases, software designed to support diagnostic or therapeutic decisions will often fall within class IIa in accordance with the much-discussed Rule 11 of Annex VIII to the MDR. If the software monitors vital physiological parameters, changes in which could pose an immediate risk to the user, it may even fall under class IIb. By contrast, if the product is primarily intended to provide information to patients without any further communication to doctors, it may commonly be classified as class I.
An additional stricter rule applies to contraceptive products: Under Rule 15 of Annex VIII to the MDR, contraceptive products are generally classified as class IIb – and implantable or invasive devices intended for long-term use are even classified as class III. An app that provides a contraceptive function based on menstrual cycle data is therefore typically subject to significantly stricter regulations than a simple menstrual cycle app with no contraceptive claims.
Depending on the class, the scope of the requirements varies: the essential safety and performance requirements set out in Annex I of the MDR, a clinical evaluation – which typically involves clinical trials for higher classes – a quality management system, a technical dossier, involvement of a notified body for the conformity assessment generally for class IIa and higher, a CE marking, a post-market surveillance system and registration in the European EUDAMED database. Class IIb devices also typically require more comprehensive clinical evidence than class I or class IIa devices.
Women's health marketing: When do advertising claims become a risk?
Particularly in the field of women's health, which is so strongly characterised by empowerment and educational communication, thoughtless marketing can alter regulatory classification. Phrases such as "suitable for reliable contraception", "detects early signs of PCOS" or "aids diagnosis of endometriosis" suggest an intended medical purpose – regardless of the product's technical features. If a company has made a conscious decision to position a product as a lifestyle tool, it must consistently align all its communications – instructions for use, website, app store description, social media and collaborations with doctors or influencers – with this position.
Conclusion: Consider regulatory classification right from the start
Regulatory classification of a women's health product is not a mere formality to be dealt with at the last minute; it is a strategic decision that affects product design, communication and market access in equal measure. Suppliers that assess early into which class if any their product fits within the scope of the MDR avoid costly later adjustments but can also make targeted use of the opportunities associated with classification as a medical device – such as access to reimbursement schemes or expanded opportunities for collaboration with gynaecologists.